| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/24/2009 | US20090238816 Method for immunizing an avian species |
| 09/24/2009 | US20090238815 Nondegradable Hydrogels For Medical Device Application |
| 09/24/2009 | US20090238762 Method for treating joint damage |
| 09/24/2009 | US20090238758 Random and non-random alkylene oxide polymer alloy compositions |
| 09/24/2009 | US20090238757 Methods and Compositions for Administering Therapeutic and Diagnostic Agents |
| 09/24/2009 | US20090238755 Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen |
| 09/24/2009 | US20090238754 Use of pyrene to carry peptides across the blood brain barrier |
| 09/24/2009 | CA2718942A1 Auristatin drug linker conjugates |
| 09/24/2009 | CA2718884A1 Heat shock protein gp96 vaccination and methods of using same |
| 09/24/2009 | CA2718854A1 Inhibition of angiogenesis |
| 09/24/2009 | CA2718749A1 The calcium sensor stim1 and the platelet soc channel orai1 (cracm1) are essential for pathological thrombus formation |
| 09/24/2009 | CA2718634A1 Antibodies against interleukin-10-like cytokines and uses therefor |
| 09/24/2009 | CA2718473A1 Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
| 09/24/2009 | CA2718430A1 Improvements in preparation of influenza virus vaccine antigens |
| 09/24/2009 | CA2718081A1 Von willebrand factor specific binders and methods of use therefor |
| 09/24/2009 | CA2717569A1 Methods for treating psoriasis |
| 09/24/2009 | CA2717071A1 Methods of treatment using anti-mif antibodies |
| 09/24/2009 | CA2716592A1 Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| 09/24/2009 | CA2714708A1 Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase |
| 09/24/2009 | CA2709981A1 Pre- or post-exposure treatment for filovirus or arenavirus infection |
| 09/23/2009 | EP2103691A1 T helper cell epitopes |
| 09/23/2009 | EP2103629A1 Gamma -1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
| 09/23/2009 | EP2103628A1 Anti-claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same |
| 09/23/2009 | EP2103311A1 The calcium sensor STIM1 is essential for pathological thrombus formation |
| 09/23/2009 | EP2102345A1 Rsv f-protein and use thereof |
| 09/23/2009 | EP2102245A1 Polyvalent bioconjugates |
| 09/23/2009 | EP2102243A2 Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use |
| 09/23/2009 | EP2102242A1 Antibodies against insulin-like growth factor i receptor and uses thereof |
| 09/23/2009 | EP2102235A1 Treatment of cachexia |
| 09/23/2009 | EP2101877A2 Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo |
| 09/23/2009 | EP2101823A2 Rna-coded antibody |
| 09/23/2009 | EP2101818A1 Binding agents to the integrin alpha-11 subunit, and uses thereof |
| 09/23/2009 | EP2101815A2 Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
| 09/23/2009 | EP2101814A1 Carbohydrate specific cellular immunity inducing microorganisms and fractions thereof |
| 09/23/2009 | EP2101812A1 Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
| 09/23/2009 | EP2101811A2 Vaccine for periodontitis and methods of use |
| 09/23/2009 | EP2101807A2 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| 09/23/2009 | EP2101805A2 Specific therapy and medicament using integrin ligands for treating cancer |
| 09/23/2009 | EP2101801A1 Oral delivery of polypeptides |
| 09/23/2009 | EP2101780A2 Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| 09/23/2009 | EP1888631B1 Therapeutic composition for use in the prevention and treatment of bone metastases |
| 09/23/2009 | EP1773999B1 Vaccine for prevention and treatment of hiv-infection |
| 09/23/2009 | EP1706428B1 Anti-cancer antibodies with reduced complement fixation |
| 09/23/2009 | EP1667715B1 Antigen delivery system |
| 09/23/2009 | EP1558758B1 Molecular identification of aspergillus species |
| 09/23/2009 | EP1542528B1 A method of treatment and prophylaxis |
| 09/23/2009 | EP1478662B1 Method for producing hypoallergenic major birch pollen allergens rbet v 1 |
| 09/23/2009 | EP1326887B1 Polypeptide from haemophilus influenza |
| 09/23/2009 | EP1097213B1 Vaccine against staphylococcus intoxication |
| 09/23/2009 | EP1086138B1 Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
| 09/23/2009 | EP1073734B1 Tumor associated nucleic acids and uses therefor |
| 09/23/2009 | EP0863981B1 Detection, prevention and treatment of papillomatous digital dermatitis |
| 09/23/2009 | CN101541345A Stabilized antibody formulations and uses thereof |
| 09/23/2009 | CN101541344A Immunization protocol against the 4 dengue serotypes |
| 09/23/2009 | CN101541343A Use of clostridium perfringens type C bacterium for the manufacture of a vaccine |
| 09/23/2009 | CN101541342A Means and method for raising improved immune response |
| 09/23/2009 | CN101538574A Codon-optimized cholera enterotoxin CTB gene and cholera nucleic acid vaccine thereof |
| 09/23/2009 | CN101538550A Helicobacter pylori viable bacteria carrier vaccine and special recombination bacteria thereof |
| 09/23/2009 | CN101538328A Humanized neutralizing engineered antibody for targeting avian influenza virus H5N1 |
| 09/23/2009 | CN101538327A Anthropogenic H5N1-resisting hemagglutinin protein broad-spectrum neutralising antibody and application thereof |
| 09/23/2009 | CN101538326A Variable region sequence of hepatitis B virus monoclonal antibody, gene engineering antibody containing variable region and application thereof |
| 09/23/2009 | CN101538319A Polypeptide for detecting polytype human papilloma virus and application thereof |
| 09/23/2009 | CN101537186A Vaccine freeze-drying protective agent without gelatin |
| 09/23/2009 | CN101537180A Recombinant production of mixtures of antibodies |
| 09/23/2009 | CN101537179A Long-acting animal rabies vaccine and preparing method thereof |
| 09/23/2009 | CN101537178A Method for filing nitrogen in partial vacuum after freezing out rabies vaccine |
| 09/23/2009 | CN101537176A Application of staphylococcus lysozyme compound in preparing medicament improving animal health condition |
| 09/23/2009 | CN101537015A Application of carbon nano-tubes in immunity accelerators for preparing anti-tumor immunotherapy medicaments |
| 09/23/2009 | CN100543140C Vector for anti-HPV vaccine and transformed microorganism by the vector |
| 09/23/2009 | CN100542607C Anti-myelin associated glycoprotein (MAG) antibodies |
| 09/23/2009 | CN100542606C Vaccine composition comprising tumour antigen and adjuvant composition |
| 09/23/2009 | CN100542605C Nucleic acid coated particles |
| 09/22/2009 | US7593723 Modular personal device system |
| 09/22/2009 | US7592437 Genes involved in intestinal inflammatory diseases and use thereof |
| 09/22/2009 | US7592431 Biodegradable T-cell Activation device |
| 09/22/2009 | US7592428 monoclonal antibodies binds specifically to the extracellular domain; useful in diagnostic methods, enzyme-linked immunosorbent assay; use in therapy to modulate activin or transforming growth factor activity; biodrugs for fibrosis, liver cirrhosis and pulmonary fibrosis, cancer, rheumatoid arthritis |
| 09/22/2009 | US7592425 antibody binds a polypeptide; use in tissue targeted therapy; Interleukins; immunoglobulins; for stimulating proliferation and/or development of hematopoietic cells in vitro and in vivo; polypeptide-toxins |
| 09/22/2009 | US7592372 Mixture of fudostein, acid and sweetening |
| 09/22/2009 | US7592318 88kDa tumorigenic growth factor and antagonists |
| 09/22/2009 | US7592315 Peptide viral entry inhibitors |
| 09/22/2009 | US7592313 Method of stimulating proliferation of regulatory T cells in a diabetic mammal |
| 09/22/2009 | US7592171 Vibrio cholerae with improved biological safety features in freeze dried form |
| 09/22/2009 | US7592169 Methods and compositions for treatment and prevention of HSV-2 infections and conditions |
| 09/22/2009 | US7592158 Polypeptides and polynucleotides, including vaccines against bacterial infections such as otitis media in infants and children, and pneumonia in elderlies |
| 09/22/2009 | US7592149 Can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization |
| 09/22/2009 | US7592135 High resolution typing system for pathogenic Mycobacterium tuberculosum |
| 09/22/2009 | US7592014 Stabilized viral envelope proteins and uses thereof |
| 09/22/2009 | US7592013 Administering a recombant food-grade bacterium expressing a trefoil peptide;delivering a TFF1 trefoil peptide in vivo expressed by a Lactococcus for lesion damage to the mucous membranes of the mouth caused by radiation; antinflammatory agents; gastrointestinal disorders |
| 09/22/2009 | US7592012 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same |
| 09/22/2009 | US7592011 Streptococcal peptide for use in prevention and treatment of microorganismal infection; bactericides; microbiocides |
| 09/22/2009 | US7592010 Extending the shelf life of Therapeutic protein X; nucleic acids and vectors containing them; kits; treating, preventing, or ameliorating diseases, disorders or conditions |
| 09/22/2009 | US7592009 Polypeptide ligands for targeting cartilage and methods of use thereof |
| 09/22/2009 | US7592008 Membrane scaffold proteins |
| 09/22/2009 | US7592007 Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies |
| 09/22/2009 | US7592006 Composition comprising the LO-CD2a antibody |
| 09/22/2009 | US7592005 Multiple myeloma; targeting antibody conjugated with a radionuclide or other cytotoxic substance |
| 09/22/2009 | US7592004 Lyophilizing an aqueous formulation comprising a high concentration, 50 mg/ml or more of an immunoglobulin IgG antibody, in particular, daclizumab, in 5-25 mM histidine buffer, having pH 5.5-6.5, 0.005%-0.03% polysorbate, and sucrose |
| 09/22/2009 | US7591997 Method for determining the susceptibility of a subject to infection |
| 09/22/2009 | US7591994 Camptothecin-binding moiety conjugates |
| 09/22/2009 | CA2508139C Escape mutants of newcastle disease virus as marker vaccines |